Addendum
Dabrafenib/trametinib - Addendum to Commissions A15-39 and A15-40
Report documents
-
Addendum
Dabrafenib/trametinib - Addendum to Commissions A15-39 and A15-40
Press releases
Dabrafenib/trametinib: considerable added benefit for men with advanced melanoma
Study data subsequently submitted allow quantification / still major added benefit for women
Additional information
Federal Joint Committee (G-BA)
2016-03-17 A G-BA decision was published on trametinib.
G-BA documents on this decision
2016-03-17 A G-BA decision was published on dabrafenib.
Project details
- Project no.
- A16-05
- Commission
- Commission awarded on 09.02.2016 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently on the extent of the added benefit, thus completing the early benefit assessment: decides-dabrafenib / decides-trametinib
Connected Projects
-
Dossier assessment
Dabrafenib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Trametinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed